Actively Recruiting
Short Versus Long-term Levetiracetam in Brain Tumors
Led by Tata Memorial Centre · Updated on 2026-02-13
604
Participants Needed
2
Research Sites
360 weeks
Total Duration
On this page
Sponsors
T
Tata Memorial Centre
Lead Sponsor
M
Manipal Academy for Higher Education
Collaborating Sponsor
AI-Summary
What this Trial Is About
Levetiracetam is the commonly preferred anti-seizure medicine in patients with brain tumors. This drug has reduced the risk of seizure events occurring but is associated with a risk of side effects such as increased headache, drowsiness, loss of muscle coordination, and psychological challenges in patients. In patients undergoing appropriate treatment for brain tumors and controlled of seizures in the initial few months of levetiracetam, the chance of further seizures is relatively low. The optimal duration to give levetiracetam is not well defined for these patients, and currently as standard treatment levetiracetam is continued for 2-3 years. This study aims to answer this question by comparing patients on a short course of levetiracetam (experimental arm) versus a longer course of levetiracetam (standard arm), with the anticipation that a shorter duration of treatment will not lead to increased seizure episodes.
CONDITIONS
Official Title
Short Versus Long-term Levetiracetam in Brain Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- History of seizure
- Histological diagnosis of primary brain tumor
- Supratentorial location of primary tumor
- Controlled on levetiracetam monotherapy for 6 months
- Index surgery within 1 year
- Karnofsky Performance Scale (KPS) 50 or higher
You will not qualify if you...
- Karnofsky Performance Scale (KPS) less than 50
- No history of seizure
- Unclear history of seizure episodes in the past
- Use of antiepileptics other than levetiracetam in the previous 6 months
- No histological diagnosis
- Progressive disease
- Brain metastasis
- Altered mental status with deficits in understanding or inability to consent to the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Manipal Academy of Higher Education
Udupi, Karnataka, India, 576104
Not Yet Recruiting
2
Tata Memorial Centre
Mumbai, Maharashtra, India, 400012
Actively Recruiting
Research Team
A
Archya Dasgupta, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here